IMPACT

2014: FPWR funds the screening of 10,000 small molecules in search of drug candidates.

2019: Potential drug candidates are in pre-clinical testing for safety and efficacy.

2019

IMPACT

2014

2019

2014: FPWR co-funds the Phase 1 study of Diazoxide Choline (DCCR).

2019: DESTINY-PWS begins its Phase 3 clinical trial in the U.S. and U.K.

IMPACT

2019

2015: FPWR launches the Global PWS Registry to establish a comprehensive natural history of PWS.

2019:

More than 2,000 patients are enrolled.

PATH for PWS, a 4-year, $1M study into serious medical events, is launched within the Registry.

The registry is used to develop a new clinical trial endpoint measuring anxiety and distress.

IMPACT

2015: FPWR establishes the PWS Clinical Trials Consortium to encourage collaboration and leverage the expertise of industry, academia and patient organizations.

2019: Treatment preferences for people with PWS are published to help guide the FDA for future drug approvals.

IMPACT

2019

2017 / 2018: FPWR individually awards Drs. Chamberlain and Carmichael pilot funding from for their work in PWS genetics research.

2019: Drs. Chamberlain and Carmichael, University of Connecticut, receive a $3M collaborative grant from the NIH to further their work on the molecular underpinnings of PWS.